Treatment of lung cancer cell lines resistant to the EGFR monoclonal antibody cetuximab with the c-Src inhibitor dasatinib, led to a loss of nuclear EGFR and a re-sensitization to cetuximab treatment (Figure 1) [88]. Here, EGFR is linked to lung carcinoma.